Cbd for neuropathic pain
Pro Research Analysisby 
Searched over 200M research papers
CBD for Neuropathic Pain: Clinical and Preclinical Evidence
Clinical Trials on CBD for Neuropathic Pain Relief
Recent clinical studies have explored the effectiveness of cannabidiol (CBD) for neuropathic pain, but results are mixed. A large, randomized, placebo-controlled trial in patients with multiple sclerosis (MS) or spinal cord injury (SCI) found that CBD, either alone or combined with THC, did not significantly reduce neuropathic pain or spasticity compared to placebo over six weeks of treatment . Similarly, a review of randomized controlled trials concluded that studies using CBD alone showed no significant analgesic effect over placebo, though these studies were small and short in duration . Another clinical trial using oral capsules of THC, CBD, or their combination for peripheral neuropathic pain found the evidence to be weak against recommending cannabinoids for this indication .
Topical CBD and Peripheral Neuropathy
In contrast to oral or systemic administration, a randomized, placebo-controlled trial found that topical CBD oil significantly reduced intense pain, sharp pain, cold, and itchy sensations in patients with peripheral neuropathy of the lower extremities, with no reported adverse events . This suggests that topical CBD may offer symptomatic relief for some patients with peripheral neuropathy.
Preclinical Studies: Mechanisms and Efficacy
Animal studies provide more consistent evidence supporting CBD’s potential for neuropathic pain relief. In rodent models, systemic or peripheral administration of CBD reversed mechanical and thermal allodynia, hyperalgesia, and anxiety-like behaviors associated with neuropathic pain 23410. These effects were dose-dependent and involved several mechanisms, including activation of CB1, CB2, TRPV1, and 5-HT1A receptors 23410. CBD also reduced neuroinflammation by targeting FKBP5, a protein involved in inflammatory signaling, and inhibited microglia activation in the spinal cord .
CBD Extracts vs. Pure CBD
Some preclinical research suggests that high-CBD cannabis extracts may be more effective than pure CBD in reducing neuropathic pain, possibly due to the presence of other plant compounds that enhance the anti-nociceptive effects . However, pure CBD alone showed limited impact on mechanical hypersensitivity in certain models .
Safety and Tolerability
Across clinical and preclinical studies, CBD was generally well tolerated, with few or no adverse events reported, especially with topical application .
Conclusion
While preclinical studies consistently show that CBD can reduce neuropathic pain and related symptoms through multiple biological pathways, clinical evidence in humans is less robust, with most trials showing limited or no benefit for oral or systemic CBD. Topical CBD may provide relief for peripheral neuropathy symptoms. More large, high-quality clinical trials are needed to clarify CBD’s role in neuropathic pain management and to determine which formulations and routes of administration are most effective.
Sources and full results
Most relevant research papers on this topic